Physician profile
Bill H Halmi
NPI 1245226042
$4,073.89
in general payments reported to CMS, 2019-2025
28 companies · $647 in 2025
The $647 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $464 · 2021: $633 · 2022: $382 · 2023: $724 · 2024: $682 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.13 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,527.77 | 2019-2025 | |
| Amgen INC. | $227.56 | 2019-2024 | Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $222.32 | 2020-2025 | Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $218.02 | 2020-2025 | Dupixent |
| Janssen Biotech, INC. | $190.76 | 2021-2025 | Tremfya |
| Genentech USA, INC. | $179.04 | 2019-2025 | Xolair |
| Dermavant Sciences, INC. | $178.22 | 2023-2024 | Vtama |
| Leo Pharma INC. | $123.42 | 2023-2025 | Anzupgo, Adbry |
| Allergan, INC. | $118.57 | 2019-2022 | |
| Lilly USA, LLC | $101.46 | 2020-2023 | Taltz |
| Arcutis Biotherapeutics, INC. | $98.02 | 2023-2025 | Zoryve |
| Genzyme Corporation | $93.00 | 2021-2025 | |
| Ucb, INC. | $91.76 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $87.70 | 2019-2025 | Jublia |
| Pfizer INC. | $86.78 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $82.27 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $73.93 | 2023-2024 | Sotyktu |
| Biofrontera INC. | $69.10 | 2021-2022 | |
| Botanix Sb INC | $67.65 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.64 | 2022-2023 | Spevigo |
| Almirall LLC | $38.22 | 2019-2020 | |
| Galderma Laboratories, L.P. | $34.29 | 2019-2025 | Nemluvio |
| Incyte Corporation | $30.87 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $22.56 | 2020 | |
| Dusa Pharmaceuticals, INC. | $19.55 | 2019 | |
| Kyowa Kirin, INC. | $18.73 | 2022 | |
| Dermira, INC. | $17.15 | 2021 | |
| Nabriva Therapeutics, Plc | $15.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bill Halmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.